Maurice-Williams R S
Br Med J. 1978 Apr 15;1(6118):945-7. doi: 10.1136/bmj.1.6118.945.
The outcome of treatment with an antifibrinolytic agent (tranexamic acid) for six weeks after rupture of an intracranial aneurysm was assessed in a randomised controlled trial. Twenty-two out of 25 (88%) treated patients survived at follow-up of three to 33 months compared with 14 out of 25 (56%) control patients. Among the patients who did not undergo operation the survival rate was 81% (13 out of 16) in treated patients and 42% (8 out of 19) in controls. Antifibrinolytic treatment has so far been assumed merely to postpone rebleeding and has been used to enable surgery to be deferred. These findings suggest that tranexamic acid may actually prevent rebleeding without operation. Prolonged antifibrinolysis may therefore prove useful in those patients in good condition whose aneurysms do not lend themselves to surgical obliteration.
在一项随机对照试验中,评估了颅内动脉瘤破裂后使用抗纤溶药物(氨甲环酸)进行六周治疗的效果。在3至33个月的随访中,25例接受治疗的患者中有22例(88%)存活,而25例对照患者中有14例(56%)存活。在未接受手术的患者中,治疗组的存活率为81%(16例中的13例),对照组为42%(19例中的8例)。迄今为止,抗纤溶治疗仅被认为是推迟再出血,并被用于使手术能够延期进行。这些发现表明,氨甲环酸实际上可能在不进行手术的情况下预防再出血。因此,延长抗纤溶治疗可能对那些病情良好但动脉瘤不适合手术闭塞的患者有用。